ANX-007

Phase 2 ARCHER trial data demonstrates ANX007's ability to preserve vision in patients with dry AMD and geographic atrophy, showing significant protection across multiple visual function measures.

Astellas Pharma has submitted a New Drug Application to Japan's MHLW for avacincaptad pegol, potentially becoming the first approved treatment for geographic atrophy in Japan.

The dry age-related macular degeneration (AMD) therapeutic landscape is robust, with over 70 companies developing more than 80 therapies.

Annexon anticipates a Biologics License Application (BLA) submission for ANX005 in the first half of 2025, potentially transforming Guillain-Barré Syndrome (GBS) treatment.

Annexon, Inc. (ANNX) has made significant progress in developing treatments for neuroinflammatory diseases, with recent announcements including the expansion of its board of directors, positive results from clinical trials, and participation in major healthcare conferences.